Stamakort®
RESEARCH RESULTS
As a result of the studies, it was found that the use of STAMAKORT® helped to smooth the clinical
manifestations of chronic gastritis in 86% of cases, and the most significant effect was observed in
persons of the older age group, in whom signs of atrophic changes in the gastric mucosa were noted
during the fibrogastroscopy.
The laboratory examination of gastric juice showed insufficiency of the secretory function of the stom-
ach in the examined patients of both groups before treatment (Table 2).
The indices of total acidity and free hydrochloric acid in patients of both groups were at the lower
limit of the norm before treatment, which was clinically manifested by symptoms of hypoacidity. Af-
ter treatment with conventional means in patients of the control group, the indicators of total acidity
and free hydrochloric acid increased, respectively, from 24.2 ± 2.1 mmol/l to 31.4 ± 2.4 mmol/l, and
in patients of the primary group - up to 37, 1 ± 1.8 mmol/l, which is significantly higher than in the
control group (p <0.05). The same trend was observed when studying the dynamics of changes in the
indicator of the content of free hydrochloric acid. As a result of the action of STAMAKORT®, there
was an optimization of indices of gastric secretory function in patients of the primary group since the
index of total acidity, and the content of free hydrochloric acid approached normal values.
Influence of STAMAKORT®on gastric secretory function in patients with Table 2
chronic gastritis.
Indicators Before Treatment After Treatment
Control Group Primary Group Control Group Primary Group
Total acidity on an empty stomach, (mmol/l) 24,2±2,1 22,6±1,7 31,4±2,4* 37,1±1,8*#
Free HCl, (mmol/l) 11,3±1,1 14,3±1,7 15,9±1,3* 19,2±1,5*
HCl flow rate, (mmol/h) 1,21±0,08 1,13±0,01 1,57±0,05 1,86±0,03
Free HCl flow rate, (mmol/h) 0,56±0,03 0,72±0,04 0,79±0,07 0,96±0,04
* - p <0.05 compared with the indicator in the same group before treatment.
# - p <0.05 compared to the same indicator in the control group.
When examining the contents of the gastric juice in patients of the primary group in the process of
taking STAMAKORT®, there was an increase in gastric acidity, a decrease in inflammatory changes in
the gastric mucosa, and a reduction in mucus and food debris in the test portions taken on an empty
stomach, which indicate an increase in the secretory and evacuation functions of the stomach.
Clinical patients noted a decrease in the manifestations of dyspeptic disorders, a decrease in pain syn-
drome, and improved well-being.
The normalization of digestion in patients with chronic disease is associated with the regulatory ef-
fect of STAMAKORT®, not only on the function of the gastric and duodenal mucosa cells but also by
stimulating the enzymatic activity of the duodenal contents.
Thus, the results obtained indicate the effectiveness of STAMAKORT® and the advisability of its use
in the complex treatment of chronic gastritis.
STAMAKORT® does not cause side effects, complications, or drug dependence.
STAMAKORT® can be used for therapeutic and prophylactic purposes in the form of a biologically
active food supplement and in combination with any means of symptomatic and pathogenetic thera-
py used to treat chronic gastritis.
CONCLUSION
Biologically active food additive STAMAKORT®has a normalizing effect on metabolism in the gastric
mucosa tissues.
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.